Advertisement

HindustanTimes Thu,25 Dec 2014

Aurobindo Pharma gets USFDA nod for anti-migraine tablets

PTI  Hyderabad, January 01, 2013
First Published: 14:15 IST(1/1/2013) | Last Updated: 14:17 IST(1/1/2013)

Drug maker Aurobindo Pharma Ltd on Tuesday said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Advertisement

The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said.

Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co's Maxalt Tablets of equivalent dose and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

The annual sale of the product is approximately $300 million for 12 months ending March 2012 according to IMS data, the release said.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.

Aurobindo now has a total of 171 abbreviated new drug application (ANDA) approvals (146 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA, according to Aurobindo.

Aurobindo scrip is traded at Rs. 193.25 apiece on BSE in the afternoon trade.


Advertisement
more from India

Talk like Atal Bihari Vajpayee: Some of the best speeches by the former PM

Vajpayee was often commended for his ability to stump his critics, especially in Parliament, with a passionate speech. Perhaps, one of his most memorable Parliament address was from 1996 during the confidence vote of his 13-day-old BJP government.
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved